Dr Behzad Hajarizadeh

Razavi-Shearer D; Gamkrelidze I; Nguyen MH; Chen DS; Van Damme P; Abbas Z; Abdulla M; Abou Rached A; Adda D; Aho I, 2018, 'Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 383 - 403, http://dx.doi.org/10.1016/S2468-1253(18)30056-6

Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio H; Hajarizadeh B; Hayes PC; Krajden M, 2018, 'Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study', Journal of Viral Hepatitis, vol. 25, pp. 473 - 481, http://dx.doi.org/10.1111/jvh.12837

Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 153 - 161, http://dx.doi.org/10.1016/S2468-1253(17)30404-1

Martinello M; Hajarizadeh B; Dore GJ, 2018, 'Observations on the launch of new drugs for hepatitis C', Australian Prescriber, vol. 41, pp. 4 - 5, http://dx.doi.org/10.18773/austprescr.2018.005

Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia', Journal of Viral Hepatitis, vol. 25, pp. 640 - 648, http://dx.doi.org/10.1111/jvh.12852

Cunningham EB; Hajarizadeh B; Amin J; Bretana N; Dore GJ; Degenhardt L; Larney S; Luciani F; Lloyd AR; Grebely J, 2018, 'Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study', International Journal of Drug Policy, vol. 54, pp. 18 - 25, http://dx.doi.org/10.1016/j.drugpo.2017.12.013

Esmaeili A; Mirzazadeh A; Morris MD; Hajarizadeh B; Sacks HS; Maher L; Grebely J; Kim AY; Lauer G; Cox AL, 2018, 'The Effect of Female Sex on Hepatitis C Incidence among People Who Inject Drugs: Results from the International Multicohort InC3 Collaborative', Clinical Infectious Diseases, vol. 66, pp. 20 - 28, http://dx.doi.org/10.1093/cid/cix768

Shepherd SJ; McDonald SA; Palmateer NE; Gunson RN; Aitken C; Dore GJ; Goldberg DJ; Applegate TL; Lloyd AR; Hajarizadeh B, 2018, 'HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype', Journal of Medical Virology, vol. 90, pp. 120 - 130, http://dx.doi.org/10.1002/jmv.24919

Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M, 2017, 'The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study', Journal of Hepatology, http://dx.doi.org/10.1016/j.jhep.2017.10.019

Grebely J; Hajarizadeh B; Dore GJ, 2017, 'Direct-Acting antiviral agents for HCV infection affecting people who inject drugs', Nature Reviews Gastroenterology and Hepatology, vol. 14, pp. 641 - 651, http://dx.doi.org/10.1038/nrgastro.2017.106

Hajarizadeh B; Mesgarpour B; Nasiri MJ; Alavian SM; Merat S; Poustchi H; Malekzadeh R; Sedaghat A; Haghdoost AA, 2017, 'Estimating the prevalence of hepatitis B virus infection and exposure among general population in Iran', Hepatitis Monthly, vol. 17, http://dx.doi.org/10.5812/hepatmon.11715

Wallace J; Smith E; Hajarizadeh B; Richmond J; Lucke J, 2017, 'Addressing cultural diversity: the hepatitis B clinical specialist perspective', Ethnicity and Health, pp. 1 - 13, http://dx.doi.org/10.1080/13557858.2017.1370540

Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression', Journal of Hepatology, vol. 67, pp. 1204 - 1212, http://dx.doi.org/10.1016/j.jhep.2017.07.025

Wallace J; Pitts M; Liu C; Lin V; Hajarizadeh B; Richmond J; Locarnini S, 2017, 'More than a virus: A qualitative study of the social implications of hepatitis B infection in China', International Journal for Equity in Health, vol. 16, http://dx.doi.org/10.1186/s12939-017-0637-4

Bajis S; Dore GJ; Hajarizadeh B; Cunningham EB; Maher L; Grebely J, 2017, 'Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review', International Journal of Drug Policy, vol. 47, pp. 34 - 46, http://dx.doi.org/10.1016/j.drugpo.2017.07.002

Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020

Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, vol. 17, http://dx.doi.org/10.1186/s12879-017-2517-3

Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040

Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4

Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M, 2017, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse', Journal of Clinical Virology, vol. 92, pp. 32 - 38, http://dx.doi.org/10.1016/j.jcv.2017.05.007

Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2017, 'HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs', Current HIV/AIDS Reports, pp. 1 - 12, http://dx.doi.org/10.1007/s11904-017-0358-8

Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR, 2017, 'Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study', Journal of Viral Hepatitis, vol. 24, pp. 733 - 741, http://dx.doi.org/10.1111/jvh.12701

Blach S; Zeuzem S; Manns M; Altraif I; Duberg AS; Muljono DH; Waked I; Alavian SM; Lee MH; Negro F, 2017, 'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 161 - 176, http://dx.doi.org/10.1016/S2468-1253(16)30181-9

Hajarizadeh B; Grebely J; McManus H; Estes C; Razavi H; Gray RT; Alavi M; Amin J; McGregor S; Sievert W, 2017, 'Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment', Journal of Gastroenterology and Hepatology (Australia), vol. 32, pp. 229 - 236, http://dx.doi.org/10.1111/jgh.13453

Esmaeili A; Mirzazadeh A; Carter GM; Esmaeili A; Hajarizadeh B; Sacks HS; Page KA, 2017, 'Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis', Journal of Viral Hepatitis, vol. 24, pp. 117 - 127, http://dx.doi.org/10.1111/jvh.12628

Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ, 2016, 'Hepatitis C treatment as prevention: evidence, feasibility, and challenges', The Lancet Gastroenterology and Hepatology, vol. 1, pp. 317 - 327, http://dx.doi.org/10.1016/S2468-1253(16)30075-9

Alavi M; Law MG; Grebely J; Amin J; Hajarizadeh B; George J; Dore GJ, 2016, 'Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study', Journal of Hepatology, vol. 65, pp. 879 - 887, http://dx.doi.org/10.1016/j.jhep.2016.06.025

Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)', Journal of Hepatology, vol. 65, pp. 1086 - 1093, http://dx.doi.org/10.1016/j.jhep.2016.08.010

Alavian SM; Hajarizadeh B; Lankarani KB; Sharafi H; Daryani NE; Merat S; Mohraz M; Mardani M; Fattahi MR; Poustchi H, 2016, 'Recommendations for the clinical management of hepatitis C in Iran: A consensus-based national guideline', Hepatitis Monthly, vol. 16, http://dx.doi.org/10.5812/hepatmon.guideline

Hajarizadeh B; Richmond J; Ngo N; Lucke J; Wallace J, 2016, 'Hepatitis B-related concerns and anxieties among people with chronic hepatitis B in Australia', Hepatitis Monthly, vol. 16, http://dx.doi.org/10.5812/hepatmon.35566

Hajarizadeh B; Razavi-Shearer D; Merat S; Alavian SM; Malekzadeh R; Razavi H, 2016, 'Liver disease burden of hepatitis C virus infection in Iran and the potential impact of various treatment strategies on the disease burden', Hepatitis Monthly, vol. 16, http://dx.doi.org/10.5812/hepatmon.37234

Sheridan DA; Hajarizadeh B; Fenwick FI; Matthews GV; Applegate T; Douglas M; Neely D; Askew B; Dore GJ; Lloyd AR, 2016, 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection', Liver International, vol. 36, pp. 1774 - 1782, http://dx.doi.org/10.1111/liv.13176

Hajarizadeh B; Lamoury FMJ; Feld JJ; Amin J; Keoshkerian E; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Grebely J, 2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, vol. 13, http://dx.doi.org/10.1186/s12985-016-0482-x

Lamoury FMJ; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR, 2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, vol. 16, http://dx.doi.org/10.1186/s12879-016-1567-2

Bartlett SR; Jacka B; Bull RA; Luciani F; Matthews GV; Lamoury FMJ; Hellard ME; Hajarizadeh B; Teutsch S; White B, 2016, 'HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection', Infection, Genetics and Evolution, vol. 37, pp. 252 - 258, http://dx.doi.org/10.1016/j.meegid.2015.11.028

Richmond J; Hajarizadeh B; Wallace J, 2015, 'Patients' perspectives on the delivery of hepatitis B management and care', Australian family physician, vol. 44, pp. 346

Hajarizadeh B; Wallace J; Richmond J; Ngo N; Enright C, 2015, 'Hepatitis B knowledge and associated factors among people with chronic hepatitis B', Australian and New Zealand Journal of Public Health, vol. 39, pp. 563 - 568, http://dx.doi.org/10.1111/1753-6405.12378

Lamoury FMJ; Bartlett S; Jacka B; Hajarizadeh B; Grebely J; Matthews GV; Dore GJ; Applegate TL, 2015, 'Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types', Journal of Molecular Diagnostics, vol. 17, pp. 583 - 589, http://dx.doi.org/10.1016/j.jmoldx.2015.05.003

Sibley A; Han KH; Abourached A; Lesmana LA; Makara M; Jafri W; Salupere R; Assiri AM; Goldis A; Abaalkhail F, 2015, 'The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - Volume 3', Journal of Viral Hepatitis, vol. 22, pp. 21 - 41, http://dx.doi.org/10.1111/jvh.12476

Sacks-Davis R; Grebely J; Dore GJ; Osburn W; Cox AL; Rice TM; Spelman T; Bruneau J; Prins M; Kim AY, 2015, 'Hepatitis c virus reinfection and spontaneous clearance of reinfection - The InC³study', Journal of Infectious Diseases, vol. 212, pp. 1407 - 1419, http://dx.doi.org/10.1093/infdis/jiv220

Alfaleh FZ; Nugrahini N; Matičič M; Tolmane I; Alzaabi M; Hajarizadeh B; Valantinas J; Kim DY; Hunyady B; Abaalkhail F, 2015, 'Strategies to manage hepatitis C virus infection disease burden - Volume 3', Journal of Viral Hepatitis, vol. 22, pp. 42 - 65, http://dx.doi.org/10.1111/jvh.12474

Liakina V; Hamid S; Tanaka J; Olafsson S; Sharara AI; Alavian SM; Gheorghe L; El Hassan ES; Abaalkhail F; Abbas Z, 2015, 'Historical epidemiology of hepatitis C virus (HCV) in select countries - Volume 3', Journal of Viral Hepatitis, vol. 22, pp. 4 - 20, http://dx.doi.org/10.1111/jvh.12475

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC³study', Journal of Viral Hepatitis, vol. 22, pp. 708 - 717, http://dx.doi.org/10.1111/jvh.12384

Hajarizadeh B; Wallace J; Richmond J; Ngo N; Enright C, 2015, 'Hepatitis B knowledge and associated factors among people with chronic hepatitis B', Australian and New Zealand Journal of Public Health, http://dx.doi.org/10.1111/1753-6405.12378

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2015, 'Patterns of hepatitis C Virus RNA levels during acute infection: The InC³ study', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0122232

Hajarizadeh B; Grebely J; Applegate T; Matthews GV; Amin J; Petoumenos K; Hellard M; Rawlinson W; Lloyd A; Kaldor J, 2014, 'Dynamics of HCV RNA Levels During Acute Hepatitis C Virus Infection', Journal of Medical Virology, vol. 86, pp. 1722 - 1729, http://dx.doi.org/10.1002/jmv.24010

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC³Study', Journal of Clinical Virology, vol. 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027

Keshvari M; Sharafi H; Hajarizadeh B; Alavian SM, 2014, 'Can we include genetic variants with high linkage disequilibrium into a multiple logistic model?', Liver International, vol. 34, pp. 964 - 964, http://dx.doi.org/10.1111/liv.12464

Grebely J; Hajarizadeh B; Dore GJ; Grady B; Page K, 2014, 'Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?', Hepatology, http://dx.doi.org/10.1002/hep.26675

Keshvari M; Pouryasin A; Behnava B; Sharafi H; Hajarizadeh B; Alavian SM, 2014, 'Letter: The rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C', Alimentary Pharmacology and Therapeutics, vol. 39, pp. 343, http://dx.doi.org/10.1111/apt.12589

Mirzazadeh A; Salimzadeh H; Arabi M; Hajarizadeh B; Navadeh S; Haghdoost AA, 2013, 'Trends of obesity in Iranian adults from 1990s to late 2000s; a Systematic Review and Meta-analysis', Middle East Journal of Digestive Diseases, vol. 5, pp. 151 - 157, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990178/

Grebely J; Page K; Sacks-Davis R; van der Loeff MS; Rice TM; Bruneau J; Morris MD; Hajarizadeh B; Amin J; Cox AL, 2013, 'The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection', Hepatology, http://dx.doi.org/10.1002/hep.26639

Wallace J; Hajarizadeh B; Richmond J; McNally S, 2013, 'Challenges in managing patients in Australia with chronic hepatitis B: The General Practitioners' perspective', Australian and New Zealand Journal of Public Health, vol. 37, pp. 405 - 410, http://dx.doi.org/10.1111/1753-6405.12127

Hajarizadeh B; Grebely J; Dore GJ, 2013, 'Epidemiology and natural history of HCV infection', Nature Reviews Gastroenterology and Hepatology, vol. 10, pp. 553 - 562, http://dx.doi.org/10.1038/nrgastro.2013.107

Wallace J; McNally S; Richmond J; Hajarizadeh B; Pitts M, 2012, 'Challenges to the effective delivery of health care to people with chronic hepatitis B in Australia', Sexual Health, vol. 9, pp. 131 - 137, http://dx.doi.org/10.1071/SH10137

Wallace J; Hajarizadeh B; Richmond J; McNally S; Pitts M, 2012, 'Managing chronic hepatitis B The role of the GP', Australian Family Physician, vol. 41, pp. 893 - 898

Hajarizadeh B; Grebely J; Dore GJ, 2012, 'Case definitions for acute hepatitis C virus infection: A systematic review', Journal of Hepatology, vol. 57, pp. 1349 - 1360, http://dx.doi.org/10.1016/j.jhep.2012.07.007

Wallace J; McNally S; Richmond J; Hajarizadeh B; Pitts M, 2011, 'Managing chronic hepatitis B: A qualitative study exploring the perspectives of people living with chronic hepatitis B in Australia', BMC Research Notes, vol. 4, http://dx.doi.org/10.1186/1756-0500-4-45

Alavian SM; Mohammad-Alizadeh AH; Esna-Ashari F; Ardalan G; Hajarizadeh B, 2009, 'Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures', Liver International, vol. 29, pp. 159 - 163, http://dx.doi.org/10.1111/j.1478-3231.2008.01790.x

Tavallaii SA; Mirzamani M; Heshmatzade Behzadi A; Assari S; Khoddami Vishteh HR; Hajarizadeh B; Einollahi B, 2009, 'Sexual function: A comparison between male renal transplant recipients and hemodialysis patients', Journal of Sexual Medicine, vol. 6, pp. 142 - 148, http://dx.doi.org/10.1111/j.1743-6109.2008.01047.x

Movahedi M; Hajarizadeh B; Rahimi A; Arshinchi M; Amirhosseini K; Haghdoost AA, 2009, 'Trends and geographical inequalities of the main health indicators for rural Iran', Health Policy and Planning, vol. 24, pp. 229 - 237, http://dx.doi.org/10.1093/heapol/czp007

Alavian SM; Gooya MM; Hajarizadeh B; Esteghamati AR; Moeinzadeh AM; Haghazali M; Zamani GA; Yaghini F; Lankarani KB, 2009, 'Mass vaccination campaign against hepatitis B in adolescents in Iran: Estimating coverage using administrative data', Hepatitis Monthly, vol. 9, pp. 189 - 195

Shariat-Torbaghan S; Emami-Aleagha M; Sedighi S; Azadbakht F; Keshvari A; Hajarizadeh B; Rosai J, 2009, 'Squamous cell carcinoma arising in an ovarian mature cystic teratoma: A case report', Archives of Iranian Medicine, vol. 12, pp. 186 - 189

Sali S; Alavian SM; Hajarizadeh B, 2008, 'Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients', Nephrology, vol. 13, pp. 376 - 379, http://dx.doi.org/10.1111/j.1440-1797.2008.00952.x

Movahedi M; Haghdoost AA; Pournik O; Hajarizadeh B; Fallah MS, 2008, 'Temporal variations of health indicators in Iran comparing with other Eastern Mediterranean Region countries in the last two decades', Journal of Public Health, vol. 30, pp. 499 - 504, http://dx.doi.org/10.1093/pubmed/fdn071

Alavian SM; Hajarizadeh B; Ahmadzad-Asl M; Kabir A; Bagheri-Lankarani K, 2008, 'Hepatitis B virus infection in Iran: A systematic review', Hepatitis Monthly, vol. 8, pp. 281 - 294

Haghdoost AA; Sadeghirad B; Hajarizadeh B; Mirzazadeh A, 2007, 'The application of Systematic Review and Meta-analysis concepts in summarizing the findings of observational studies', Iranian Journal of Psychiatry, vol. 2, pp. 132 - 136, http://ijps.tums.ac.ir/index.php/ijps/article/view/453

Mirmomen S; Alavian SM; Hajarizadeh B; Kafaee J; Yektaparast B; Zahedi MJ; Zand V; Azami AA; Hosseini MMA; Faridi AR, 2006, 'Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with beta-thalassemia in Iran: A multicenter study', Archives of Iranian Medicine, vol. 9, pp. 319 - 323

Jahani MR; Alavian SM; Shirzad H; Kabir A; Hajarizadeh B, 2005, 'Distribution and risk factors of hepatitis B, hepatitis C, and HIV infection in a female population with "illegal social behaviour" [9]', Sexually Transmitted Infections, vol. 81, pp. 185, http://dx.doi.org/10.1136/sti.2004.011114

Alavian SM; Hajarizadeh B; Hajibeigi B; Doroudi T; Hamedianizadeh AK; Abar K, 2004, 'Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranians', Hepatitis Monthly, vol. 4, pp. 53 - 58, http://hepatmon.portal.tools/?page=article&article_id=668

Alavian SM; Hajarizadeh B, 2004, 'Attempted suicide in two patients with chronic hepatitis C while being treated with Interferon-alpha', Hepatitis Monthly, vol. 4, pp. 20 - 22, http://hepatmon.portal.tools/?page=article&article_id=691

Alavian SM; Kabir A; Hajarizadeh B; Nayebpour M; Haji Beigi B; Doroudi T; Baralle F, 2004, 'Combination Therapy of Interferon-alpha (PDferon B®) and Ribavirin for Chronic Hepatitis C', Hepatitis Monthly, vol. 4, pp. 13 - 16, http://hepatmon.portal.tools/?page=article&article_id=689

Alavian SM; Hajarizadeh B, 2004, 'Remarkable difference in the mode of HCV transmission among haemodialysis patients and IVDAs [7]', Gut, vol. 53, pp. 1057

Alavian SM; Hajarizadeh B; Nematizadeh F; Larijini B, 2004, 'Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease', BMC Endocrine Disorders, vol. 4, http://dx.doi.org/10.1186/1472-6823-4-4

Einollahi B; Hajarizadeh B; Bakhtiari S; Lesanpezeshki M; Khatami MR; Nourbala MH; Pourfarziani V; Alavian SM, 2003, 'Pretransplant hepatitis C virus infection and its effect on the post-transplant course of living renal allograft recipients', Journal of Gastroenterology and Hepatology (Australia), vol. 18, pp. 836 - 840, http://dx.doi.org/10.1046/j.1440-1746.2003.03063.x

Alavian SM; Einollahi B; Hajarizadeh B; Bakhtiari S; Nafar M; Ahrabi S, 2003, 'Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients', Nephrology, vol. 8, pp. 256 - 260, http://dx.doi.org/10.1046/j.1440-1797.2003.00166.x

Einollahi B; Hajarizadeh B; Simforoosh N; Lessanpezeshki M; Khatami MR; Nourbala MH; Basiri A; Pourfarziani V; Firoozan A; Nafar M, 2003, 'Patient and graft outcome after living donor renal transplantation in Iran: More than 15-year follow-up', Transplantation Proceedings, vol. 35, pp. 2605 - 2606, http://dx.doi.org/10.1016/j.transproceed.2003.09.075

Simforoosh N; Basiri A; Pourrezagholi F; Einolahi B; Firouzan A; Moghaddam MM; Nourbala MH; Hajarizadeh B; Pourfarziani V; Lessanpezeshki M, 2003, 'Is preemptive renal transplantation preferred?', Transplantation Proceedings, vol. 35, pp. 2598 - 2601, http://dx.doi.org/10.1016/j.transproceed.2003.09.026

Alavian SM; Hajarizadeh B; Einollahi B, 2003, 'Efficacy and safety of lamivudine for treatment of chronic hepatitis B in renal allograft recipients', Transplantation Proceedings, vol. 35, pp. 2687 - 2688, http://dx.doi.org/10.1016/j.transproceed.2003.08.042

Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 'Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014).', Hepatol Commun, vol. 1, pp. 736 - 747, http://dx.doi.org/10.1002/hep4.1073

Lamoury F; Soker A; Martinez D; Hajarizadeh B; Cunningham E; Bruggmann P; Foster G; Dalgard O; Conway B; Robaeys G, 2016, 'HEPATITIS C VIRUS CORE ANTIGEN: A SIMPLIFIED TREATMENT MONITORING TOOL, INCLUDING FOR POST-TREATMENT RELAPSE', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Barcelona, SPAIN, Vol. 64, pp. S625 - S626, presented at EASL International Liver Congress, Barcelona, SPAIN, 13 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01163-6

Cunningham EB; Luciani F; Hajarizadeh B; Betz-Stablein B; Bretana NA; Teutsch S; Dore GJ; Grebely J; Lloyd AR, 2016, 'STABLE INCIDENCE OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING, 2005-2014: THE HITS-P STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Barcelona, SPAIN, Vol. 64, pp. S614 - S614, presented at EASL International Liver Congress, Barcelona, SPAIN, 13 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01138-7

Hajarizadeh B; Grebely J; Matthews G; Martinello M; Dore G, 2016, 'Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments', in HEPATOLOGY, WILEY, Boston, MA, Vol. 64, pp. 948A - 948A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493804277&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews G; Law M; Dore G, 2016, 'Survival following hepatocellular carcinoma among people with HBV or HCV in New South Wales, Australia between 2000 and 2014', in HEPATOLOGY, WILEY, Boston, MA, Vol. 64, pp. 886A - 886A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493804156&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Hajarizadeh B; Grebely J; Byrne M; Marks P; Butler T; Amin J; Vickerman P; Martin NK; McHutchison JG; Brainard DM, 2016, 'Hepatitis C virus exposure, infection and associated risk behaviours in two maximum-security prisons in New South Wales, Australia', in HEPATOLOGY, WILEY, Boston, MA, Vol. 64, pp. 385A - 386A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Grebely J; Dalgard O; Conway B; Foster G; Bruggmann P; Backmund M; Robaeys G; Swan T; Hajarizadeh B; Amin J, 2015, 'EFFICACY OF RESPONSE-GUIDED PEGYLATED INTERFERON AND RIBAVIRIN THERAPY FOR PEOPLE WHO INJECT DRUGS WITH HCV GENOTYPE 2/3 INFECTION: THE ACTIVATE STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, Vol. 62, pp. S657 - S657, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 22 - 26 April 2015, http://dx.doi.org/10.1016/S0168-8278(15)31050-3

Hajarizadeh B; Grady B; Page K; Kim AY; Mcgovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: The InC3 study', in Journal of Viral Hepatitis, Blackwell Publishing Ltd, http://dx.doi.org/10.1111/jvh.12384

Sheridan DA; Hajarizadeh B; Matthews G; Applegate TL; Douglas MW; Askew B; Neely D; Bassendine MF; Dore GJ; Lloyd AR, 2014, 'Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection', in HEPATOLOGY, WILEY-BLACKWELL, Boston, MA, Vol. 60, pp. 929A - 929A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, 07 - 11 November 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804082&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Hajarizadeh B; Grady BP; Page K; Kim AY; McGovern BH; Cox A; Rice TM; Sacks-Davis R; Bruneau J; Morris MD, 2014, 'Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study', in HEPATOLOGY, WILEY-BLACKWELL, Boston, MA, Vol. 60, pp. 898A - 899A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, 07 - 11 November 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a